Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Steinfeld

Orthopaedic Surgery Vero Beach, FL Medical Doctor

NPI 1851391619 CMS profile 83635

1285 36Th St, Ste 100, Vero Beach, FL 32960

Open in the dashboard

General payments

$409,110

368 records reported · program years 2019–2025

Research payments

$19,029

Paid to them · 4 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$7,888 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Richard Steinfeld of Vero Beach, FL is reported in the CMS Open Payments database as having received $409,110 across 368 general payments and $19,029 in research payments paid to them. Separately, studies naming them as principal investigator received $7,888 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28,044 39
2024 General $24,356 37
2024 Research $19,029 4
2023 General $51,743 56
2022 General $166,214 92
2021 General $51,777 80
2020 General $24,366 23
2019 General $62,611 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Steinfeld
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Richard Steinfeld were reported at $28,044. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Richard Steinfeld Orthopaedic Surgery median Middle half National median
2019 $62,611 $644 $140–$2,844 $163
2020 $24,366 $312 $75–$1,860 $114
2021 $51,777 $520 $117–$2,495 $132
2022 $166,214 $598 $128–$2,731 $149
2023 $51,743 $461 $128–$2,264 $160
2024 $24,356 $497 $134–$2,475 $164
2025 $28,044 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Uoc USA Inc $166,667 69 payments
  2. Smith+Nephew, Inc. $162,372 131 payments
  3. Globus Medical, Inc. $55,670 47 payments
  4. Shalby Advanced Technologies, Inc. $11,678 18 payments
  5. Stryker Corporation $3,171 26 payments
  6. Kyocera Medical Technologies, Inc. $3,128 3 payments
  7. Maxx Orthopedics, Inc. $3,094 15 payments
  8. Medacta USA, Inc. $1,117 10 payments
  9. Zimmer Biomet Holdings, Inc. $833 12 payments
  10. Carbofix Orthopedics Inc $371 5 payments
  11. Other $1,009 32 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $227,069 58 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $107,670 17 payments
  3. Travel and Lodging $60,119 95 payments
  4. Food and Beverage $14,230 197 payments
  5. Royalty or License $23 1 payment
Products named General payments · program years 2019–2025
  1. POLARSTEM $86,843 42 payments
  2. JOURNEY II Recon Knees $64,024 23 payments
  3. JOURNEY II Recon Knees $62,774 17 payments
  4. TANDEM $56,934 32 payments
  5. U2 UOC Knee System $53,731 8 payments
  6. OR3O Dual Mobility $48,798 20 payments
  7. POLARCUP $46,850 10 payments
  8. U2 United Knee System $38,460 8 payments
  9. REAL INTELLIGENCE $26,196 26 payments
  10. U2 PSI $25,547 7 payments
  11. Other $244,604 356 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Maxx Orthopedics, Inc. $19,029 4 payments

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

1,976

Median for Orthopedic Surgery: 203

Drug cost

$12,881

Median for Orthopedic Surgery: $1,433

Branded share of claims

23.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 349 $3,326
Methylprednisolone Generic 339 $2,731
Celecoxib Generic 130 $1,939
Tramadol Hcl Generic 494 $1,854
Cephalexin Generic 107 $601
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 79 $594
Ondansetron Hcl Generic 112 $558
Meloxicam Generic 131 $414
Ondansetron Odt Ondansetron Brand 44 $384
Amoxicillin Generic 133 $250

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 108 billing codes

Paid by Medicare

$402,172

Of which drugs: $14,745

Medicare patients

977

Average age 77

Services billed

18,677

587 women, 390 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 31%
Osteoporosis 22%
Chronic kidney disease 21%
Diabetes 20%
Atrial fibrillation 20%
Cancer 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivitive, genvisc 850, for intra-articular injection, 1 mg J7320 Office 33 2,963 $12,110
Injection, methylprednisolone acetate, 1 mg J1010 Office 216 10,711 $1,078
Injection, methylprednisolone acetate, 40 mg J1030 Office 98 116 $459

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $6
$6 — —
Exparel
  • Pacira Pharmaceuticals Incorporated $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

372 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record